SJT Molecular Research
Preclinical biotechnology company focused on discovery and early development of orally active small-molecule candidates for metabolic disorders (NAFLD/NASH, obesity, hypertension, dyslipidemia, type 2 diabetes). Core activities include medicinal chemistry and SAR-driven lead optimization, multi-step synthesis and scale-up, analytical development and batch-level QC, in vivo pharmacology in rodent and non-mammalian models (OGTT, DIO-NASH, SHR), ADME/PK profiling, preclinical safety testing (including genotoxicity assays), computational target prediction and mechanism-of-action studies, and coordination with academic and CRO partners. The portfolio is protected by international patent families and patent documents include detailed synthetic, analytical and preclinical experimental data.
Industries
Nr. of Employees
small (1-50)
SJT Molecular Research
Calle Paraguay 19 bajo, 01012 Vitoria-Gasteiz, Álava, España
Patents
Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis
US-10857136-B2
View Details
Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis
US-10857136-B2
View DetailsProducts
Lead orally bioavailable small-molecule candidate series for metabolic disease
A portfolio of orally active substituted heterocyclic small molecules developed to modulate metabolic-syndrome endpoints (glucose regulation, insulin sensitivity, weight control, blood pressure, dyslipidemia, hepatic steatosis) supported by synthetic chemistry, analytical characterization, PK data, in vivo efficacy and safety studies.
Lead orally bioavailable small-molecule candidate series for metabolic disease
A portfolio of orally active substituted heterocyclic small molecules developed to modulate metabolic-syndrome endpoints (glucose regulation, insulin sensitivity, weight control, blood pressure, dyslipidemia, hepatic steatosis) supported by synthetic chemistry, analytical characterization, PK data, in vivo efficacy and safety studies.
Services
Evaluation and execution of licensing, partnering and R&D collaborations for preclinical small-molecule programs, providing access to compound series and supporting experimental data packages.
Provision of multi-step synthesis, process optimization, intermediate isolation, salt formation, scale-up to preparative batches, and analytical characterization to generate material and data packages for preclinical evaluation or licensing.
Evaluation and execution of licensing, partnering and R&D collaborations for preclinical small-molecule programs, providing access to compound series and supporting experimental data packages.
Provision of multi-step synthesis, process optimization, intermediate isolation, salt formation, scale-up to preparative batches, and analytical characterization to generate material and data packages for preclinical evaluation or licensing.
Expertise Areas
- Preclinical small-molecule drug discovery for metabolic disorders
- Medicinal chemistry and diversity-oriented analogue generation
- Multi-step synthesis and preparative scale-up for preclinical supply
- In vivo pharmacology using rodent models (OGTT, DIO-NASH, SHR) and non-mammalian screening (Drosophila)
Key Technologies
- Diversity-oriented and multi-step organic synthesis
- High-performance liquid chromatography (HPLC/LC-MS)
- Nuclear magnetic resonance spectroscopy (NMR)
- Molecular docking and molecular dynamics simulations
News & Updates
Patent filings and granted patents in jurisdictions including USA, Europe, Japan, Canada, Australia and others covering the compound family and indicated uses.
Preclinical program data include pharmacokinetics, reduction of NAFLD activity score and liver lipids, decreased insulin resistance and body weight in DIO/NASH models, and blood pressure and lipid reductions in hypertensive rat models; mechanism studies indicate activity at nuclear receptor and GPCR targets.
Acute and repeat-dose oral toxicity studies (including repeat dosing up to 250 mg/kg for 14 days) reported without systemic toxicity; no mutagenic activity in bacterial reverse mutation assays and negative in vivo micronucleus results up to reported dose levels.
Patent documents contain detailed synthetic procedures, batch-level reaction conditions, analytical purity data and preclinical pharmacology (OGTT, hypertensive rat studies) supporting candidate claims.
Patent filings and granted patents in jurisdictions including USA, Europe, Japan, Canada, Australia and others covering the compound family and indicated uses.
Preclinical program data include pharmacokinetics, reduction of NAFLD activity score and liver lipids, decreased insulin resistance and body weight in DIO/NASH models, and blood pressure and lipid reductions in hypertensive rat models; mechanism studies indicate activity at nuclear receptor and GPCR targets.
Acute and repeat-dose oral toxicity studies (including repeat dosing up to 250 mg/kg for 14 days) reported without systemic toxicity; no mutagenic activity in bacterial reverse mutation assays and negative in vivo micronucleus results up to reported dose levels.
Patent documents contain detailed synthetic procedures, batch-level reaction conditions, analytical purity data and preclinical pharmacology (OGTT, hypertensive rat studies) supporting candidate claims.